Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials

被引：0
|
作者：
Herbel, N. [1 ]
Ouali, K. [1 ]
Danlos, F-X. [1 ]
Massard, C. P. [1 ]
Goldschmidt, V. [1 ]
Michot, J-M. [1 ]
Laparra, A. [2 ]
Bernard-Tessier, A. [3 ]
Gazzah, A. [1 ]
Bahleda, R. [1 ]
Hollebecque, A. [1 ]
Henon, C. [1 ]
Postel-Vinay, S. [1 ]
Loriot, Y. [1 ]
Ribrag, V. [1 ]
Marabelle, A. [1 ]
Fizazi, K. [3 ]
Aix, S. Ponce [1 ]
Champiat, S. [1 ]
Baldini, C. [1 ]
机构：
[1] Inst Gustave Roussy, Drug Dev Dept, Villejuif, France
[2] Inst Gustave Roussy, DIOPP, Villejuif, France
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.723
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657P
引用
收藏
页码：S519 / S519
页数：1
相关论文
共 50 条
  • [31] Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
    Friedman, C.
    Williams, A. De Burgh
    Lopez, J. S.
    Ouali, K.
    Middleton, M. R.
    Thistlethwaite, F.
    Hamid, O.
    Izar, B.
    Garcia, V. Moreno
    Johnson, M. L.
    Davar, D.
    Martin-Liberal, J.
    Roxburgh, P.
    Moore, K. N.
    Olson, D.
    Rottey, S.
    Kirk, P. B.
    Yuan, Y.
    Marshall, S.
    Yeku, O.
    ANNALS OF ONCOLOGY, 2024, 35 : S569 - S570
  • [32] Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
    Cheng, Pingyan
    Chen, Xianghong
    Dalton, Robert
    Calescibetta, Alexandra
    So, Tina
    Gilvary, Danielle
    Ward, Grace
    Smith, Victoria
    Eckard, Sterling
    Fox, Judith A.
    Guenot, Jeanmarie
    Markowitz, Joseph
    Cleveland, John L.
    Wright, Kenneth L.
    List, Alan F.
    Wei, Sheng
    Eksioglu, Erika A.
    MOLECULAR THERAPY, 2022, 30 (06) : 2315 - 2326
  • [33] Locoregional treatment of low-grade B-cell lymphoma with CD3 x CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation
    Manzke, O
    Tesch, H
    Borchmann, P
    Wolf, J
    Lackner, K
    Gossmann, A
    Diehl, V
    Bohlen, H
    INTERNATIONAL JOURNAL OF CANCER, 2001, 91 (04) : 508 - 515
  • [34] Erratum: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
    S Hipp
    Y-T Tai
    D Blanset
    P Deegen
    J Wahl
    O Thomas
    B Rattel
    P J Adam
    K C Anderson
    M Friedrich
    Leukemia, 2017, 31 : 2278 - 2278
  • [35] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
    Wong, Sandy W.
    Bar, Noffar
    Paris, Laura
    Hofmeister, Craig C.
    Hansson, Markus
    Santoro, Armando
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Lund, Johan
    Encinas, Cristina
    Yee, Andrew J.
    Oriol, Albert
    Cerchione, Claudio
    de la Rubia, Javier
    Ferstl, Barbara
    Carlson, Kristina
    Ribas, Paz
    Bermudez, Arancha
    Boss, Isaac W.
    Gaudy, Allison
    Li, Shaoyi
    Hsu, Kevin
    Godwin, Colin D.
    Burgess, Michael R.
    San-Miguel, Jesus
    Costa, Luciano J.
    BLOOD, 2022, 140
  • [36] CD3 × CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation
    An Willems
    Steve Schoonooghe
    Dominique Eeckhout
    Geert De Jaeger
    Johan Grooten
    Nico Mertens
    Cancer Immunology, Immunotherapy, 2005, 54 : 1059 - 1071
  • [37] Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
    Wermke, M.
    Gambardella, V.
    Kuboki, Y.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Villaruz, L.
    Studeny, M.
    Bouzaggou, M.
    Fang, X.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S32 - S32
  • [38] A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
    Kebenko, Maxim
    Goebeler, Marie-Elisabeth
    Wolf, Martin
    Hasenburg, Annette
    Seggewiss-Bernhardt, Ruth
    Ritter, Barbara
    Rautenberg, Beate
    Atanackovic, Djordje
    Kratzer, Andrea
    Rottman, James B.
    Friedrich, Matthias
    Vieser, Eva
    Elm, Stefanie
    Patzak, Ingrid
    Wessiepe, Dorothea
    Stienen, Sabine
    Fiedler, Walter
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [39] A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors
    Li, Feng
    Liu, Ming
    Hua, Yanan
    Wei, Xuemei
    Qin, Luying
    Cao, Guangcan
    Yang, Daniel Chunxu
    Zhang, Wenjun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro
    Cheng, Pingyan
    Eksioglu, Erika
    Chen, Xianghong
    Wei, Max
    Guenot, Jeanmarie
    Fox, Judy
    List, Alan F.
    Wei, Sheng
    BLOOD, 2017, 130
12345